Evidence map›Paper›PMID 35116558›Full record

ArticleTranslational cancer research2021

A systematic review and meta-analysis of the influence of STAS on the long-term prognosis of stage I lung adenocarcinoma.

Yanhui Yang, Xiaoyang Xie, Yi Wang, Xiaoliang Li, Lei Luo, Yi Yao, Ji Li

Abstract read
In one paragraph

Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yanhui YangDepartment of Thoracic Surgery, The First People's Hospital of Neijiang, Neijiang, China.
Xiaoyang XieDepartment of Thoracic Surgery, The First People's Hospital of Neijiang, Neijiang, China.
Yi WangDepartment of Thoracic Surgery, The First People's Hospital of Neijiang, Neijiang, China.
Xiaoliang LiDepartment of Thoracic Surgery, The First People's Hospital of Neijiang, Neijiang, China.
Lei LuoDepartment of Thoracic Surgery, The First People's Hospital of Neijiang, Neijiang, China.
Yi YaoDepartment of Thoracic Surgery, The First People's Hospital of Neijiang, Neijiang, China.
Ji LiDepartment of Thoracic Surgery, The First People's Hospital of Neijiang, Neijiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe appearance of airway dissemination often indicates poor prognosis of lung cancer. However, the relationship between airway dissemination and early lung adenocarcinoma is not clear. Therefore, this study uses meta-analysis to study the long-term prognosis of patients with early lung adenocarcinoma.

methodsA computer search of the PubMed, EMbase, Web of Science, and other databases was conducted, and the search time limit was from the establishment of the database to December 30, 2020. Data strictly in accordance with the inclusion and exclusion criteria was extracted and the quality of the included literature was evaluated. Two reviewers then independently screened the literature and evaluated the risk of bias.

resultsA total of 11 studies were included, comprised of 5,097 patients with early lung adenocarcinoma. The results of the meta-analysis showed that among patients with stage I lung adenocarcinoma, the 5-year recurrence-free survival (RFS) and overall survival (OS) of STAS-positive patients was lower than those of the STAS-negative group, and the difference was statistically significant. In the control study, the 5-year RFS was HR =1.95, 95% CI (1.58-2.31) P<0.01, and the 5-year OS was OR =2.04, 95% CI (1.60-2.48) P<0.01, and in STAS-positive patients, sublobectomy had a worse long-term prognosis than lobectomy. While the 5-year RFS HR of the lobectomy group was 1.82, 95% CI (1.43-2.22), and the 5-year RFS HR of the sublobectomy group was 6.92, 95% CI (1.64-12.18) P<0.01, the prognosis of the STAS-positive high-expression group and the low-expression group was worse. The 5-year RFS HR of the low-expression STAS group was 2.93, 95% CI (0.21-6.07), and in the high expression group this was 8.20, 95% CI (0.55-15.85) P<0.05. DISCUSSION: STAS is an independent risk factor for the poor prognosis of stage I lung adenocarcinoma and a high expression of STAS results in a higher 5-year recurrence rate. When STAS is positive, the sublobectomy method should be carefully selected. However, our research has certain limitations, such as literature selection and publication bias. At the same time, the depth of literature analysis needs to be further improved.

Indexed as

long-term prognosismeta-analysisstage I lung adenocarcinomaSTAS

Identifiers

PMID35116558
PMCPMC8797706

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.